Phase II study of efficacy of bevacizumab and erlotinib in inoperable previously untreated hepatocellular carcinoma (HCC)

被引：0
|
作者：
Govindarajan, R.
Siegel, E.
Makhoul, I.
Williamson, S.
机构：
[1] Univ Arkansas Med Sci, Little Rock, AR 72205 USA
[2] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15557
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Open-label, phase I/randomized, phase II trial of the triple angiokinase inhibitor, nintedanib, versus sorafenib in previously untreated patients with advanced hepatocellular carcinoma (HCC)
    Palmer, Daniel H.
    Peck-Radosavljevic, Markus
    Ma, Yuk Ting
    Graham, Janet
    Fartoux, Laetitia
    Hubner, Richard
    Loembe, Arsene Bienvenu
    Studeny, Matus
    Hocke, Julia
    Meyer, Tim
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [42] Phase II trial investigating the efficacy and safety of sunitinib in patients with unresectable hepatocellular carcinoma (HCC)
    Faivre, S. J.
    Raymond, E.
    Douillard, J.
    Boucher, E.
    Lim, H. Y.
    Kim, J. S.
    Lanzalone, S.
    Lechuga, M. J.
    Sherman, L.
    Cheng, A. L.
    EJC SUPPLEMENTS, 2007, 5 (04): : 270 - 270
  • [43] A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma
    Dalhoff, K
    Dancey, J
    Astrup, L
    Skovsgaard, T
    Hamberg, KJ
    Lofts, FJ
    Rosmorduc, O
    Erlinger, S
    Hansen, JB
    Steward, WP
    Skov, T
    Burcharth, F
    Evans, TRJ
    BRITISH JOURNAL OF CANCER, 2003, 89 (02) : 252 - 257
  • [44] A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma
    K Dalhoff
    J Dancey
    L Astrup
    T Skovsgaard
    K J Hamberg
    F J Lofts
    O Rosmorduc
    S Erlinger
    J Bach Hansen
    W P Steward
    T Skov
    F Burcharth
    T R J Evans
    British Journal of Cancer, 2003, 89 : 252 - 257
  • [45] Preliminary results of radiotherapy (RT) combined with sintilimab (Sin) and bevacizumab (Bev) in advanced hepatocellular carcinoma (HCC) previously treated with immune checkpoint inhibitors (ICIs): A prospective phase II study
    Xue, J.
    Tang, J.
    Lin, Z.
    Wang, J.
    Zhang, J.
    Zhang, T.
    ANNALS OF ONCOLOGY, 2023, 34 : S599 - S599
  • [46] The combination of bevacizumab (B) and erlotinib (E) shows significant biological activity in patients with advanced hepatocellular carcinoma (HCC)
    Thomas, M. B.
    Chadha, R.
    Iwasaki, M.
    Glover, K.
    Abbruzzese, J. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [47] A phase II study of atezolizumab (ATEZO) and bevacizumab (Bev) in combination with Y90 TARE in patients (Pts) with hepatocellular carcinoma (HCC).
    He, Aiwu Ruth
    Kim, Alexander Y.
    Toskich, Beau M.
    Mody, Kabir
    Kim, Kevin
    Stein, Stacey
    Goyal, Lipika
    Abrams, Thomas Adam
    Brown, Daniel
    Goff, Laura Williams
    Kim, Richard D.
    Parikh, Nainesh
    Sandow, Tyler
    Johnson, Daniel
    Iyer, Renuka V.
    Petroziello, Michael
    Krishnamurthi, Smitha S.
    Martin, Charles
    Jiang Yixing
    Akhter, Nabeel
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [48] Bevacizumab in patients (pts) with advanced hepatocellular carcinoma (HCC): Preliminary results of a phase II study with circulating endothelial cell (CEC) monitoring
    Malka, D.
    Dromain, C.
    Farace, F.
    Horn, S.
    Pignon, J.
    Ducreux, M.
    Boige, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [49] A phase II study of erlotinib (E) and bevacizumab (B) in patients (pts) with previously untreated stage IIIB/IV non-small-cell lung cancer (NSCLC)
    Smit, Egbert F.
    Dingemans, Anne-Marie C.
    Groen, Harry J.
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S411 - S411
  • [50] A phase II study of erlotinib (E) and bevacizumab (B) in patients (pts) with previously untreated stage IIIB/IV non-small cell lung cancer (NSCLC)
    Groen, H. J.
    Smit, E. F.
    Dingemans, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345